Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.
|Articles|September 18, 2013
- Fall 2013
- Volume 12
- Issue 3
HPV Infections Plummet with Vaccine
Author(s)Elizabeth Whittington
Human papillomavirus infections in female teenagers have decreased by more than half since the introduction of HPV vaccines.
Advertisement
Human papillomavirus (HPV) infections have skyrocketed during the past 20 years, yet among female teenagers, the number of HPV infections has decreased by 56 percent since the introduction of an HPV vaccine in 2006. Experts hope the decrease in infections will ultimately result in a decrease of HPV-related cancers, including anal, cervical, certain head and neck, penile and vulvar cancers.
Articles in this issue
almost 13 years ago
Lung Cancer Video Touches on Emotions and Supportalmost 13 years ago
Triple-Negative Breast Cancer: Divide and Conqueralmost 13 years ago
Future Frontier: Fighting Cancer at the Genetic Levelalmost 13 years ago
Second Chance: When Grandparents Become the Caregiversalmost 13 years ago
Supreme Court Votes Against Human Gene Patentsalmost 13 years ago
Documentary About Cancer Plannedalmost 13 years ago
Critical Mass Annual Conferencealmost 13 years ago
Superfoods Study Keeps More Men on Active Surveillancealmost 13 years ago
New Version of an Old Chemotherapy May Reduce Risk of Cardiotoxicity in AMLalmost 13 years ago
DCA Claims Don’t Tell Whole StoryAdvertisement
Related to this article
At three years, 69% of patients treated with Imfinzi and chemotherapy around surgery were alive, compared with 62% of patients treated with chemotherapy alone.
Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
A reflection on shame, vulnerability and transformation, exploring how the past shapes us and how presence can help us let go and heal.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
AJ Wyman shares his daughter’s cancer journey and why parents caring for a child with cancer must make time for their own mental health, too.
A powerful reflection on finding hope, healing and meaning through life’s challenges, inspired by the lessons and beauty found in the sea.
In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went a median of 14.3 months without their disease worsening, compared with 8.3 months with immunotherapy plus chemotherapy.
Advertisement
Advertisement
Trending on CURE
1
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
2
Top 3 Takeaways From WCLC 2026 That Patients Should Know
3
A Gift from the Sea
4
Childhood Leukemia Survivor Shares Her Experience With ALL, Relapse and CAR-T
5